Not known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk.
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Antithymocyte immunoglobulin (rabbit). |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Antithymocyte immunoglobulin (rabbit). |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Antithymocyte immunoglobulin (rabbit). |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Antithymocyte immunoglobulin (rabbit). |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Antithymocyte immunoglobulin (rabbit). |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Antithymocyte immunoglobulin (rabbit). |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Antithymocyte immunoglobulin (rabbit). |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Antithymocyte immunoglobulin (rabbit). |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Antithymocyte immunoglobulin (rabbit). |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Antithymocyte immunoglobulin (rabbit). |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Antithymocyte immunoglobulin (rabbit). |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Antithymocyte immunoglobulin (rabbit). |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Antithymocyte immunoglobulin (rabbit). |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Antithymocyte immunoglobulin (rabbit). |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Antithymocyte immunoglobulin (rabbit). |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Antithymocyte immunoglobulin (rabbit). |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Antithymocyte immunoglobulin (rabbit). |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Antithymocyte immunoglobulin (rabbit). |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Interferon alfa-2b. |
| Daclizumab | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Phenylalanine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Flunisolide. |
| Bortezomib | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bortezomib. |
| Cladribine | Antithymocyte immunoglobulin (rabbit) may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carmustine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Amsacrine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bleomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Melphalan. |